Cushing’s disease
Recordati Rare Diseases has announced the publication of positive results from the Phase III LNC 4 study, confirming the efficacy and safety of Isturisa (osilodrostat), for the treatment of Cushing’s disease.
In the Phase III trial, the oral therapy Isturisa provided rapid and sustained control of cortisol secretion in the majority of patients throughout the 48-week core phase of the study.
